RESI Boston Investor Speakers

September 9, 2026September 9, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston brings together active early-stage investors and life science innovators for two days of investor-led programming focused on capital, partnering, and market dynamics shaping healthcare innovation.

The agenda will feature leading biotech VCs, family offices, corporate scouts, health system investors, and impact-focused investors sharing how they evaluate opportunities, where they see momentum, and what founders need to understand as they prepare to raise capital and build strategic partnerships.

From Boston’s biotech ecosystem and early-stage therapeutic investing to pharma partnering, health systems, strategic capital, chronic disease, women’s health, family offices, and impact investing, the panel program offers practical insight across the full life science financing landscape.

These conversations are designed to help entrepreneurs better understand investor priorities, refine their fundraising strategy, and build relationships with the people actively shaping the future of healthcare innovation.

RESI Boston takes place in person September 22–23 at the Westin Copley Place, with virtual partnering September 25 and September 28–29. Whether attending in Boston or virtually, participants can connect with investors, gain perspective from the panel stage, and advance their next conversations through targeted partnering.

Featured RESI Boston Investor Speakers
John Abeles Northlea Partners	Marc Appel Pacific Bridge NY	Farnaz Bakhshi ACS BrightEdge
Caleb Bell Beyond Next Ventures	Alan Chiu Breakthrough T1D	Scott Davis Sontag Foundation
Ronald Dorenbos BioFrontline Ltd.	Shane Duffy Avanos Medical, Inc.	Tao Fang MRL Ventures Fund (MRLV)
David Fogel Mass Medical Angels	Navin Govind Evidence Ventures	Nimisha Gupta Jazz Pharmaceuticals, Inc
William Hsu, PhD NuFund Venture Group	Austin Hwang Analog Garage	Jonathan Ilicki Industrifonden
Renaud Jacquemart Omnium Global	Rohit Jain HBS Alumni Angels of Northern California	Satoshi Konagai Astellas Venture Management (AVM)
Jason Kraus Boston Harbor Angels	Kathy Ku Sazze Partners	Sally Wang Liang Xpanse Venture
Nate Macht ACS BrightEdge	Nune Martiros Paladin Capital Group	Andrew Merken Polsinelli PC
Nikhil Mutyal AstraZeneca	Rohit Nuwal TELUS Ventures	Maggie O'Toole LabCentral
Soyoung Park 1004 Venture Partners	Dushyant Pathak Autobahn Labs	Garrett Peterson Yahara Ventures
Andrew Rae Woodgreen Ventures	Parthiban Rajasekaran Sanofi	Armin Rump Otsuka Pharmaceutical Co., Ltd.
Mo Soleja Golden Seeds	Yvanka de Soysa Foreground Capital	Daniel Teper YADAY Health
Andrew Thomson Ipsen S.A.	John Tremblay Launchpad Venture Group	Le Zhan Yunion Healthcare Ventures

The 2027 RESI Conference Lineup: Global Capital, Strategic Partnerships, and Life Science Innovation

September 9, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

The 2027 RESI Conference Lineup: Global Capital, Strategic Partnerships, and Life Science Innovation

Life Science Nation’s 2027 RESI conference calendar will connect early-stage life science companies with global investors, pharma partners, and industry leaders across four major life science hubs: San Francisco, Tokyo, Philadelphia, and Boston.

The year begins during JPM week and continues through Asia, BIO International Convention week in Philadelphia, and Boston’s biotech week in September. Each event is designed to help emerging companies build the investor relationships and strategic partnerships needed to move their companies forward.

RESI JPM 2027: January 11–12

San Francisco Marriott Marquis, San Francisco

Registration is now open for RESI JPM 2027.

Held concurrently with JPM Healthcare Week, RESI JPM brings early-stage companies into San Francisco during one of the world’s largest annual gatherings for healthcare investment and business development. The two-day in-person conference will be followed by virtual partnering on January 13, 18, and 19.

Previous RESI JPM conferences have drawn more than 1,000 attendees, including over 600 early-stage life science investors, innovators, and industry experts. For companies raising capital, pursuing strategic partnerships, or preparing for a major financing milestone, RESI offers a focused setting to make the most of the week.

RESI Asia Japan 2027: April 13

ANA InterContinental, Tokyo

RESI Asia Japan launches in collaboration with the Kobe Biomedical Innovation Cluster (KBIC), Japan’s largest biomedical cluster.

Japan represents one of the life science industry’s most valuable and least accessible markets. Its leading pharmaceutical companies are active licensors and acquirers of external innovation, while the country offers deep clinical development capabilities and a progressive regulatory pathway for regenerative medicine, cell therapy, and gene therapy.

RESI Asia Japan will create a direct bridge between Japan’s world-class science ecosystem and global capital and partnering networks. The event is part of a broader collaboration between Life Science Nation and KBIC focused on strengthening commercialization pathways, entrepreneur education, capital formation, and international business development for Japanese life science companies.

RESI Philadelphia 2027: June 7

Convene, Philadelphia

RESI Philadelphia will take place during BIO International Convention week, complementing the broader industry activity in the city with a dedicated forum for early-stage companies and active investors.

Philadelphia is a leading center for cell and gene therapy, biopharma, medical innovation, and academic research. RESI provides companies and investors attending BIO week with a targeted environment for investor partnering, live pitch opportunities, and conversations that can turn promising science into fundable, strategic opportunities.

Virtual partnering dates will be announced soon.

RESI Boston 2027: September 22

Westin Copley Place, Boston

RESI returns to Boston during biotech week, bringing the global early-stage life science investment community together in one of the world’s most important innovation hubs.

Boston’s unmatched concentration of founders, investors, academic institutions, biotech companies, and strategic partners makes it an essential stop on the RESI calendar. The in-person event will offer targeted partnering, investor panels, educational programming, and the Innovator’s Pitch Challenge for companies seeking to raise visibility and advance fundraising conversations.

Virtual partnering dates will be announced soon.

A Global RESI Run

The 2027 lineup offers companies multiple opportunities throughout the year to engage the Life Science Nation network, deepen relationships with investors and strategic partners, and access new regional markets.

RESI JPM: January 11–12, San Francisco
RESI Asia Japan: April 13, Tokyo
RESI Philadelphia: June 7, Philadelphia
RESI Boston: September 22, Boston

Registration is now open for RESI JPM 2027. Register by October 2 to save $900 with Super Early Bird pricing. Learn more at resiconference.com.

Why It’s Not Too Late to Make the Most of RESI Partnering

September 9, 2026 ~ Next Phase Admin ~ Leave a comment

By Karen Deyo, VP of Product, Israel BD, LSN

As RESI Boston approaches, companies that have not yet registered may assume the most valuable partnering opportunities have already passed. In reality, the final two weeks before a RESI conference are often when schedules begin to fill most quickly.

Many investors and strategic partners wait until the attendee list is more complete before committing to meetings. As a result, roughly 80% of partnering meetings are typically scheduled during the last two weeks leading to the event. This is when participants are actively reviewing company profiles, prioritizing conversations, and building their final schedules.

For early-stage life science companies, that means there is still meaningful time to secure high-value meetings, but the window is narrowing. Registering now gives your team the opportunity to create a strong company profile, identify the investors and strategic partners most aligned with your stage and sector, and begin sending targeted meeting requests before calendars become full.

The most successful RESI attendees do not rely on last-minute outreach alone. They use the remaining time strategically: refine the company profile, clearly communicate the value proposition and financing objectives, research potential partners, and focus outreach on the conversations most likely to advance their next milestone.

RESI is designed to help companies turn a few concentrated days of partnering into a stronger fundraising and business-development pipeline. Whether the goal is to raise a seed or Series A round, identify strategic partners, explore licensing opportunities, or gain investor feedback, the final weeks before the conference can be some of the most productive.

It is not too late to register for RESI Boston, but now is the time to act. The sooner your company is visible on the partnering platform, the more time you will have to connect with the investors and strategic partners who can help move your business forward.

RESI Boston 2026 Innovator’s Pitch Challenge Finalists

September 1, 2026September 1, 2026 ~ Next Phase Admin ~ Leave a comment

By Max Braht, VP of Business Development, LSN

The Innovator’s Pitch Challenge (IPC) showcases early-stage companies developing breakthrough technologies across key sectors of life science and returns to RESI Boston with more than 65 innovative companies selected to pitch across 20 sessions over two days, September 22–23, 2026.

Each finalist will present to panels of active life science investors and industry leaders in sector-focused sessions spanning biotech, medtech, diagnostics, digital health, and more. The program gives fundraising companies the opportunity to share their technologies, receive practical feedback, and connect directly with investors and strategic partners seeking new opportunities.

For attendees, IPC is a chance to discover emerging companies and hear directly from the founders behind them. Finalists will also be available throughout the event exhibiting, networking, and attendees participating in partnering can schedule one-on-one meetings to continue the conversation.

Join Life Science Nation at RESI Boston during Biotech Week for two full days of company pitches, investor insights, and targeted partnering.

Meet the RESI Boston Innovator’s Pitch Challenge Finalists:

Bayer Co.Lab Joins RESI Boston 2026 as Title Sponsor

September 1, 2026September 3, 2026 ~ Next Phase Admin ~ Leave a comment

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

Life Science Nation (LSN) is excited to welcome Bayer Co.Lab as a Title Sponsor of RESI Boston 2026, taking place September 22-23 at the Westin Copley Place in Boston, with virtual partnering continuing September 25 and 28-29.

Bayer Co.Lab is Bayer’s global network of life science incubators supporting early-stage entrepreneurs developing breakthrough technologies. By connecting emerging companies with scientific expertise, mentorship, infrastructure, and Bayer’s broader global network, Co.Lab provides an environment designed to help innovators advance promising science and build the relationships needed for future growth.

Bayer Co.Lab’s mission is closely aligned with RESI’s focus on connecting early-stage life science and healthcare companies with investors, strategic partners, and industry leaders who can accelerate breakthrough therapies.

Bayer Co.Lab’s will be sponsoring a 2-hour session at RESI Boston 2026:

Connecting Asian Biotech Innovation with Global Partners: A Bayer Co.Lab Showcase

Tuesday, September 22, 2:00 – 4:00pm EST

The showcase will bring seven emerging biotechnology companies from Korea and Japan to the RESI stage, highlighting innovative approaches across various therapeutic modalities.

RSVP for Bayer Co.Lab Showcase

artiCure | Korea

Tumor-selective replicating gene therapy targeting solid tumors

Crafton Biotechnology | Japan

mRNA therapeutics supported by advanced computational approaches

Curigin | Korea

RNA-based therapeutic technologies across multiple disease areas

Elisigen | Korea

Next-generation gene therapy with programs in ophthalmology

Genome & Company | Korea

Microbiome-driven therapeutic discovery and development

ILIAS Biologics | Korea

Exosome-based therapeutics for inflammatory and fibrotic diseases

Kanjin Therapeutics | Japan

RNA therapeutics, including siRNA and antisense approaches, for areas of unmet medical need

The program reflects a growing opportunity to connect promising innovation emerging from Asian biotech ecosystems with global pharmaceutical partners, investors, and other strategic collaborators. By bringing Korean and Japanese companies directly into the RESI community, the showcase will create a forum for companies to present their science, build international relationships, and explore pathways for global development and partnership.

Meet Bayer at RESI Boston

Bayer will have a strong presence at RESI Boston, with senior representatives spanning Co.Lab and BD & Licensing departments.

Alberto Nobili Sr. Director, Strategy and Portfolio at Co.Lab	Nobuhiro Kazama Head of Collaborate to Cure Japan Hub	Ilona Gutcher Senior Director, BD&L Oncology
Carla Klattenhoff Senior Director / Scientific US Lead for Research and Early Development in CV, Renal and Immunology	Shivaranjani Sridharan Executive Director, Business Development & Licensing

Their participation gives RESI attendees an opportunity to engage with Bayer leaders representing multiple areas of scientific and strategic interest and to gain greater insight into how a global pharmaceutical company approaches external innovation and collaboration.

Bringing Global Innovators Together in Boston

RESI has always been built around a simple idea: great science can come from anywhere, but moving it forward requires the right connections.

Bayer Co.Lab’s participation as Title Sponsor of RESI Boston 2026 reinforces that mission. From supporting emerging entrepreneurs to creating new connections between Asian biotech innovators and the global life science ecosystem, the collaboration will bring another important dimension to this year’s RESI Boston.

Join Bayer Co.Lab and the global early-stage life science community at RESI Boston 2026!

Where Cross-Border Deal Flow Actually Happens

September 1, 2026September 1, 2026 ~ Next Phase Admin ~ Leave a comment

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

Every VC and PE firm says they want cross-border deal flow. Few have it. Most cross-border relationships stop at an introduction that never becomes a term sheet, because access without real syndicate standing on the other side rarely converts.

At RESI Boston 2026, Life Science Nation is convening a Cross-Border Investor Luncheon with Simon Hua, Chairman of BioMetas, to explore how cross-border access actually works through one of the hardest markets to enter.

Simon Hua
Chairman of BioMetas

Simon spent fifteen years in investment banking in Hong Kong, then a decade building and scaling the equity-for-service model that turns CRO relationships into equity stakes and syndicate seats, first at Viva Biotech, then ChemPartner, and now BioMetas. He has led CROs and his own fund, CFS Capital, to incubate and invest in over 100 innovative biotechs globally, while building an ecosystem with academic research institutions, government platforms, and VCs including Huagai Capital, E-Fund Capital, and Qiming Venture Partners.

The luncheon is built around a simple premise: bring together VCs and PE firms that want genuine syndicate relationships outside their own region, with funds that can send them deal flow and receive it in return.

Simon will speak directly to how that access works: how the equity-for-service model surfaces promising biotechs before they are broadly shopped, and how that early visibility converts into syndicate seats alongside the region’s leading investors.

Whether you are looking east or west, the practical question is the same:

How do you actually get inside?

RSVP for Cross-Border Investor Luncheon Today

*You must be an active VC investment firm that makes direct investments into life science and healthcare companies for us to approve your RSVP.

Life Science Nation (LSN) Launches RESI Asia Japan

August 25, 2026August 26, 2026 ~ Next Phase Admin ~ Leave a comment

KBIC, Title Sponsor of RESI Boston 2026 and RESI JPM 2027, Collaborates with LSN on RESI Asia Japan

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

Life Science Nation is launching RESI Asia Japan, a new conference created in collaboration with the Kobe Biomedical Innovation Cluster (KBIC), Japan’s largest biomedical cluster. The event opens April 13, 2027, at the ANA InterContinental Tokyo.

RESI Asia Japan is the culmination of a three-conference partnership, with KBIC a Title Sponsor of RESI Boston in September 2026 and RESI JPM in January 2027. Companies that attend in sequence gain three windows into the LSN network across seven months.

“Every great life science hub faces the same reality. The science is world-class, but the path from discovery to global capital remains a challenge. KBIC has done the hard part, with an elite science discovery engine. What we are building together is the bridge that carries that science into the global marketplace and carries the world’s capital and partners back to Japan.”

Dennis Ford

Founder and CEO, Life Science Nation

Why Japan matters to an early-stage company

Japan is one of the most valuable and least accessible opportunities in the industry. Takeda, Astellas, Daiichi Sankyo, Eisai, Chugai, and Ono are among the world’s most active licensors and acquirers of external innovation, and a Japan-rights deal is often early non-dilutive capital and a validation event. The PMDA offers one of the world’s most progressive routes for regenerative medicine and cell and gene therapy, where a product can earn conditional approval on demonstrated safety and probable benefit before full efficacy is proven. Japan also offers deep CRO and clinical trial capacity and is the world’s third-largest pharmaceutical market.

The obstacle is access. Arranging a first meeting with Japanese pharma, navigating PMDA, or finding the right partner is difficult from outside the region. That is what RESI Asia Japan is for.

Three challenges every life science hub shares

Every life science hub in the world faces the same three problems, no matter how strong its science.

Getting its regional assets into the global arena.
Bringing international players and stakeholders into its own region.
Getting regional and international investors to form syndicates together.

RESI was built to solve exactly these problems. The KBIC partnership puts all three to work at once.

Beyond the events, LSN and KBIC are working to strengthen the commercialization pathway for Japanese life science companies through entrepreneur education, company preparation, capital formation, and international business development.

About KBIC

KBIC brings together roughly 350 companies, research institutes, and specialized hospitals on Kobe’s Port Island, spanning regenerative medicine, medical devices, pharmaceuticals, and digital health. It sits at the center of a country that leads the world in regenerative medicine and iPS cell science.

The Redefining Early-Stage Investments (RESI) Run

RESI Boston | September 2026 | The Westin Copley Place, Boston – Register Now

RESI JPM | January 2027 | San Francisco Marriott Marquis, Union Square – Register Now

RESI Asia Japan | April 2027 | ANA InterContinental Tokyo

Learn more about RESI at RESIConference.com.

Startups seeking Japan partnerships, global capital, and an APAC foothold should register for the run in sequence, starting with RESI Boston in September.

More details on registration, agenda, and participating companies will follow in the coming months.